Select your country or region
Europe
  • Africa
  • America
  • Asia
  • Europe
  • Oceania
Select your country / region
  • Angola
  • Cape Verde
  • Egypt
  • Guinea-Bissau
  • Mozambique
  • São Tomé and Príncipe
Select your country / region
  • Australia
  • New Zealand
Select your country / region
  • Bahrain
  • Bangladesh
  • Brunei
  • Cambodia
  • China
  • Dubai (United Arab Emirates)
  • Hong Kong SAR
  • India
  • Indonesia
  • Iraq
  • Japan
  • Jordan
  • Kuwait
  • Laos
  • Lebanon
  • Malaysia
  • Oman
  • Pakistan
  • Philippines
  • Qatar
  • Saudi Arabia
  • Singapore (Asia Pacific)
  • South Korea
  • Sri Lanka
  • Taiwan, China
  • Thailand
  • Vietnam
  • Yemen
Germany
  • Andorra
  • Austria
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Gibraltar
  • Iceland
  • Ireland
  • Italy
  • Norway
  • Poland
  • Portugal
  • San Marino
  • Slovak Republic
  • Spain
  • Spain (Headquarters)
  • Sweden
  • Switzerland
  • United Kingdom
  • Vaticano
 
Select your country / region
  • Argentina
  • Aruba
  • Bolivia
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Costa Rica
  • Curacao
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Guatemala
  • Honduras
  • Mexico
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • Surinam
  • Trinidad and Tobago
  • USA
  • Uruguay
  • Venezuela

Grifols Deutschland GmbH

Grifols Deutschland was established in 1997. Based in Frankfurt, we manage the Bioscience sales in Germany, and Diagnostic sales in the German, Austrian and Swiss (DACH) markets.

We offer a comprehensive portfolio of products and services from the Bioscience, Diagnostic, Hospital and Bio Supplies divisions. Safety and quality are our top priorities as we deliver on our mission to improve the health and well-being of people around the world.

Grifols Deutschland

Colmarer Strasse 22
60528 Frankfurt am Main
GERMANY

Contact information
Tel: +49 (69) 660593100
Fax: +49 (69) 660593110

Mail: info.germany@grifols.com

Notification of adverse reactions
To report an adverse drug reaction click here

Contact with Grifols

Type of consultation *
  • Adverse event
  • Customer Service
  • Other
  • Product enquiry
  • Product technical complaint
  • Sales Visit
  • Technical Support
I have read and accept the privacy notice.
DATA PROTECTION INFORMATION
Data controller The Grifols group company to which you have submitted the request
Purpose To respond to your requests for information and/or suggestions
Legal basis Consent
Recipients Grifols group companies
Rights To access, rectify, or erase, as well as any other rights as specified in the additional information layer
Additional information You may access additional and detailed information on data protection here.

Transparency

Industry interactions with the medical profession have a profound and positive influence patient treatment and on the value of research. As primary providers of healthcare services, both healthcare professionals and healthcare organizations, offer us unique, independent insights and expert knowledge on patients' behavior and management of diseases. The capacity of gaining access to this expertise, plays a critical role in informing and guiding industry efforts to improve the quality of patient care and treatment options. And this is why, both healthcare professionals and healthcare organizations, should be fairly compensated for their contributions, as well as for the services they provide to the industry.

Industry interactions with healthcare professionals and healthcare organizations, should not only be conducted with integrity, but should also be transparent. And this is why Grifols Group fully supports, and has voluntarily adopted, the practices reflected in the new EFPIA Code of Practice and will continue to support any other country codes which promulgate transparency reporting.

In this regard, Grifols Deutschland supports transparent documentation of all collaborations with healthcare professionals and organizations and aligns its internal transparency guidelines with those of the EFPIA Code of Practice, FSA (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e. V.) Code and AKG (Arzneimittel und Kooperation im Gesundheitswesen e.V.) Code of Conduct. Based on these guidelines, Grifols Deutschland publishes, within a publicly available list, all its interactions with German-based healthcare professionals and healthcare organizations.

As of 2021 reporting exercise, these interactions are published using the EFPIA disclosure template, which are grouped and split into 4 categories: (a) Research and Development; (b) Donations; (c) Sponsoring of Educational Events; and (d) Honoraria for Services. Interactions within the category "Research and Development" are published in an aggregate format. In the other categories, interactions are to be published in an individual format, in so far as permitted under German legal requirements on personal data protection.

Commitment to patients

Every day at Grifols, patients inspire our mission to advance the discovery and development of innovative protein therapies that extend and enhance lives. We continually strive to develop new and better products and services to improve our patients' health and well-being. To further our mission, Grifols Deutschland GmbH actively supports patient organizations, programs and services that promote education, disease awareness, and patient advocacy efforts in order to improve the diagnosis and treatment of disease.